The prescription of the recombinant human TSH, Thyrogen, during the follow-up controls for patients treated for thyroid cancer significantly reduces the number and the duration of sikleave days when compared to traditional thyroid hormone withdrawal.
DE POUVOURVILLE, G., BORGET, I., CORONE, C., NOCAUDIE, M. and ALLYN, M. (2007). Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. European Journal of Endocrinology, 156(5), pp. 531-538.